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Abstract
Activating c-KIT mutations (exons 11 and 17) are found in 10–40% of testicular seminomas, the majority being missense
point mutations (codon 816). Malignant ovarian dysgerminomas represent ,3% of all ovarian cancers in Western countries,
resembling testicular seminomas, regarding chromosomal aberrations and c-KIT mutations. DSD patients with specific Y-
sequences have an increased risk for Type II Germ Cell Tumor/Cancer, with gonadoblastoma as precursor progressing to
dysgerminoma. Here we present analysis of c-KIT exon 8, 9, 11, 13 and 17, and PDGFRA exon 12, 14 and 18 by conventional
sequencing together with mutational analysis of c-KIT codon 816 by a sensitive and specific LightCycler melting curve
analysis, confirmed by sequencing. The results are combined with data on TSPY and OCT3/4 expression in a series of 16 DSD
patients presenting with gonadoblastoma and dysgerminoma and 15 patients presenting pure ovarian dysgerminomas
without DSD. c-KIT codon 816 mutations were detected in five out of the total of 31 cases (all found in pure ovarian
dysgerminomas). A synonymous SNP (rs 5578615) was detected in two patients, one DSD patient (with bilateral disease)
and one patient with dysgerminoma. Next to these, three codon N822K mutations were detected in the group of 15 pure
ovarian dysgerminomas. In total activating c-KIT mutations were found in 53% of ovarian dysgerminomas without DSD. In
the group of 16 DSD cases a N505I and D820E mutation was found in a single tumor of a patient with gonadoblastoma and
dysgerminoma. No PDGFRA mutations were found. Positive OCT3/4 staining was present in all gonadoblastomas and
dysgerminomas investigated, TSPY expression was only seen in the gonadoblastoma/dysgerminoma lesions of the 16 DSD
patients. This data supports the existence of two distinct but parallel pathways in the development of dysgerminoma, in
which mutational status of c-KIT might parallel the presence of TSPY.
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Introduction
c-KIT belongs to the Type III tyrosine kinase receptor family,
which also includes the platelet-derived growth factor receptor
(PDGFR) and macrophage-colony stimulating receptor (M-
CSFR). The ligand for c-KIT is the stem cell factor (SCF,
KITLG) and the SCF-KIT pathway regulates the differentiation
of melanocytes, red blood cells, mast cells, interstitial cells of Cajal,
and germ cells [1,2,3]. Moreover, this pathway is important in the
survival of primordial germ cells (PGCs) [4,5]. Expression of c-
KIT and gain-of-function mutations in c-KIT has been found in
mastocytosis, leukemia and gastro-intestinal stromal tumors
(GIST) [6,7,8]. In GIST activating mutations in c-KIT exons 8,
9, 11, 13 and 17 are found in 75–80% of cases, mutations in
PDGFRA exons 12, 14 and 18 in 5–8%, and they are mutually
exclusive (for review [9]).
Activating c-KIT mutations have also been found in human
germ cell tumors/cancers (GCC), and 10–40% of testicular
seminomas harbor activating mutations in exons 11 and 17.
About two thirds are missense point mutations at codon 816
[2,10,11,12], which are also found in almost all mast cell tumors
[13]. Noteworthy is that activating c-KIT mutations have been
found in a subset of tumors showing the same histology as
testicular seminoma, namely; mediastinal seminomas, intracranial
germinomas and ovarian dysgerminomas [14,15,16]. Next to
mutations in c-KIT, amplification of chromosome 4q12, harbor-
ing the c-KIT gene, has been described in testicular GCC, likely
related to the progression to seminoma [10]. Malignant ovarian
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dysgerminomas represent approximately 3% of all ovarian cancers
in Western countries, and share a morphological resemblance, and
show a similar pattern of chromosomal aberrations [17] with
testicular GCC. Families with both ovarian and testicular GCC
have been reported, suggestive of a common etiology [18].
Disorders of Sex Development (DSD), previously referred to as
intersex, are a congenital condition in which there is an atypical
development of the chromosomal, gonadal or anatomical sex [19].
DSD patients with gonadal dysgenesis or hypovirilization harbor-
ing Y-chromosomal material in their karyotype have an increased
risk of developing GCC (for review [20,21]). The precursor lesion
in the dysgenetic gonads of these patients is the gonadoblastoma
(GB), or carcinoma in situ (CIS), depending on the level of gonadal
testicularization [22]. The invasive component is the dysgermino-
ma in most cases (genetically the counterpart of the seminoma of
the testis). For the development of GB the presence of the
GonadoBlastoma locus on the Y-chromosome (GBY) is impera-
tive, with the testis specific protein, Y-linked (TSPY) gene being the
most likely candidate in this region. TSPY expression is linked to
the proliferation and survival of germ cells, and expression is
increased in CIS, GB and sometimes seminoma [23]. The
octamer-binding protein 3 (OCT3/4, POU5F1) is specifically
expressed in all GCC with pluripotent potential, as well as in the
neoplastic precursor lesions CIS and GB [24,25]. Germ cells
residing in an unfavorable environment, as is the case in DSD,
might escape cell death by prolonged expression of both OCT3/4
and TSPY. If mutations in c-KIT or PDGFRA play a significant
role in the development of GB and the development of
dysgerminoma in DSD patients is not clear so far because of the
lack of multiple studies.
Here we report the analysis of activating mutations in codon
816 of c-KIT in 31 patients with a GB and/or dysgerminoma by
LightCycler analysis, together with conventional sequence analysis
of c-KIT exons 8, 9, 11, 13 and 17, and PDGFRA exons 12, 14 and
18, mutations in which are frequently found in GIST. These
results are linked with karyotype, histology of the gonads,
expression of TSPY in the tumors and putative role of the
mutations found in the etiology of the disease.
Materials and Methods
Tissue Samples and Immunohistochemistry
In total 31 cases, consisting of eleven cases of GB, fifteen cases of
DG and eight cases of GB with DG were retrieved from the
archives (Table 1). Collected tissue samples were diagnosed
according to WHO standards [26] by an experienced pathologist
(JWO). Use of tissue samples for scientific reasons was approved by
the Medical Ethical Committee ErasmusMC (MEC 02.981 and
CCR2041). Patients gave their verbal consent that left over
material, after a diagnostic procedure, can be used for scientific
purposes. This agreement is not documented, as agreed upon by
the MEC. If patients chose to not consent, it is specifically
indicated in the clinical files, and samples were excluded. This
consent procedure was used according to the ‘‘Code for Proper
Secondary Use of Human Tissue in the Netherlands.’’
Immunohistochemistry was performed on paraffin-embedded
tissue sections of 3-mm thickness. After deparaffinization and
5 min. incubation in 3% H2O2 to inactivate endogenous
peroxidase activity, antigen retrieval was carried out by heating
under pressure of up to 1.2 bar in an appropriate buffer; 0.01 M
sodium citrate (pH 6) or 0.01 M EGTA, 0.01 M TRIS (pH 9).
After blocking endogenous biotin using the avidin/biotin blocking
kit (SP-2001, Vector Laboratories, Burlingame, CA, USA), the
sections were incubated for either 2 hrs at room-temperature
(OCT3/4, c-KIT (CD117) or overnight at 4uC (TSPY). Appro-
priate biotinylated secondary antibodies were used for detection
and were visualized using the avidin-biotin detection and substrate
kits (Vector Laboratories). The antibodies used directed against
OCT3/4, TSPY and c-KIT have been described before
[27,28,29].
DNA Isolation and c-KIT Codon 816 Mutational Screen
DNA was isolated from formalin-fixed-paraffin-embedded
material using a standard protocol, percentage of tumor present
in each sample was over 50% unless indicated otherwise (Table 1).
In brief, 10 slices of 10-mm thickness were cut and incubated three
times with xylene for at least 30 min at RT, after which the pellet
was washed each time with ethanol. Lysisbuffer consisting of
10 mM TRIS, 100 mM NaCl, 5 mM EDTA, 1% SDS and 1 mM
CaCl2 together with 10 mg/ml proteinase-K was added, and the
sample was incubated for 16 hrs at 50uC, while shaking at
1200 rpm. DNA was subsequently extracted by standard phenol/
chloroform extraction and ethanol precipitation. DNA was
dissolved in 10 mM TRIS with 1 mM EDTA. DNA quality and
concentration was checked on the Nanodrop 1000 (Thermo-
Scientific, Wilmington, DE, USA).
50 ng of DNA from each sample was screened for c-KIT
D816V, D816H, D816Y mutations using a melting-curve based
LightCycler assay (Roche Diagnostics, Mannheim, Germany) with
forward primer KIT816For, CAGCCAGAAATATCCTCCT-
TACT; or KIT816 ForA, CTTTTCTCCTCCAACCTAATAG;
reverse primer KIT816Rev, TTGCAGGACTGTCAAGCA-
GAG; and hybridization probes c-KIT-anchor, LC640-ATG-
TGGTTAAAGGAAACGTGAGTACCCA–PH; c-KIT-sensor
VAL, AGCCAGAGTCATCAAGAATGATTCTA–FL; c-KIT-
sensor TYR, AGCCAGACACATCAAGAATGATTCTA–FL; c-
KIT-sensor HIS, AGCCAGATACATCAAGAATGATTCTA.
To suppress wild type sequences, all reactions were performed
with and without addition of a locked nucleic acid (LNA), c-KIT
probe GCCAGAGACATCAAGAATG (all primers produced by
TIB molbiol, Berlin, Germany). Mixing experiments showed that
with the addition of LNA to block wild type sequence, the lower
limit of detection was 20 fg of mutant DNA in 50 ng of wild type
DNA, and routinely 20 pg of mutant DNA could be detected (data
not shown). As a control, samples containing the c.816 mutation
under investigation were included in each experiment and were
analyzed with and without LNA, together with the experimental
samples. The PCR reaction was carried out in a 20 mL volume
with 0.5 mM each of forward, reverse, anchor and appropriate
sensor probe, 0.01 mM of LNA, 3 mM MgCl2 and 2 mL Light-
Cycler Fast-Start DNA Master HybProbe mix. Reactions were
run on a LightCycler Instrument (Roche Diagnostics, Almere, The
Netherlands). Amplification was performed with 45 cycles using
60uC annealing temperature. Final melting curve analysis was
started at 40uC up to 95uC with a slope of 0.2uC /second and
continuous detection with channel F2/F1. Lightcycler data was
analyzed using the LightCycler 3.0 software (Roche Diagnostics).
Samples showing an aberrant melting curve were run at least in
duplicate.
Sequence Analysis
All cases found to be positive in the c-KIT c.816 screen were
confirmed by sequence analysis. Approximately 100 ng of PCR
product was treated with ExoSAP-IT (GE Healthcare Life
Sciences, Piscataway, NJ, USA) following manufacturers instruc-
tions, and directly sequenced with 3.3 pmol of each forward and
reverse primer using the Big Dye terminator Cycle Sequencing Kit
(Applera, Darmstadt, Germany). After initial denaturation at 95uC
c-Kit Mutations in GCC with and without DSD
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for 5 min, 25 cycles at 94uC for 15 seconds and 60uC for
4 minutes were performed. Sequence analysis was performed on
an ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City,
CA, USA).
In addition to screening for activating mutations of c.816, in all
samples c-KIT exon 8, 9, 11, 13, en 17 and PDGFRA exon 12, 14
and 18 were analyzed by conventional bidirectional cycle
sequencing of PCR-amplified fragments. Amplification of 50 ng
genomic DNA of each sample was performed with M13-tailed
primers (Table S1). After initial denaturation at 95uC for 3 min,
35 cycles of 95uC for 30 seconds, 60uC for 45 seconds, and 72uC
for 45 seconds were performed, followed by 10 min at 72uC.
Subsequent sequence analyses of the PCR products was carried
out with M13 forward and reverse primers, essentially as described
above.
Results
The mean age of diagnosis of the GB and/or DG was 15 years
(range, 3 months-36 years, see Table 1). The mean age of
diagnosis between the group of patients with DSD (cases 1–16),
being 16 (3 months-36 years) and the group with ovarian
dysgerminoma (cases 17–31), being 14 (6–19 years) did not differ
significantly. Within the group of DSD patients the mean age of
diagnosis did differ between patients showing GB, being 13 and
patients who had a dysgerminoma with GB, being 21 years. In
total, twenty-two cases showed a dysgerminoma component;
thirteen patients had pure dysgerminoma, three patients had non-
dysgerminoma components (yolk sac tumor and (immature)
teratoma) next to the dysgerminoma component, and six patients
showed GB next to dysgerminoma. One patient showed teratoma
and yolk sac tumor next to GB. Eight patients did not have an
invasive component; seven showed GB (one bilaterally) and one
patient had GB next to CIS and intratubular seminoma. Five cases
presented with bilateral disease; one case showing GB in both
gonads, one patient having GB in one gonad and GB together
with dysgerminoma in the other, one case with GB in one gonad
and GB next to dysgerminoma, yolk sac tumor and immature
teratoma in the other, and from two cases only material from one
of the gonads was available, showing GB, CIS, and dysgerminoma
in one patient and GB, teratoma and yolk sac tumor in the other
patient (cases 1–5, Table 1).
LightCycler analysis detected variants in exon 17 of c-KIT in
five out of the total group of 31 patients (19%). Four were found in
the group of ovarian dysgerminomas (27%: four out of fifteen
cases), consisting of two D816V, one D816H and one D816Y
mutation (cases 17, 19, 22 and 25, Table 1). All mutations at
codon 816 were detected in the LightCycler assay, in analyses with
and without LNA added, showing a shift in melting curves which
were compared with control samples (Figure S1). One variant in c-
KIT exon 17 was found in the group of DSD patients, which
changed the codon 178 sequence from ATC to ATT (I798I),
which encodes a known synonymous SNP (rs. 55789615) (case 4,
Table 1). This variation shifted the melting curve to a position
different from that of any of the control mutation samples included
(data not shown). Two other samples produced an aberrant
melting curve (case 1 and 2, Table 1), but no mutation was
detected in subsequent sequencing, despite analyzing the samples
in triplicate for all three c.816 variants on two independent DNA
isolations (data not shown). All mutations found were verified by
sequencing the LightCycler products from reactions with and
without LNA (Figure S1). All other samples tested showed melting
curves identical to non-mutated Asp 816 (data not shown).T
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Next to the c.816 LightCycler analysis, conventional Sanger
sequencing of c-KIT exons 8, 9, 11, 13, and 17 was performed on
the DNA samples in a diagnostic setting. This confirmed the
presence of the four c.816 mutations found by the LightCycler
analysis (cases 17, 19, 22 and 25, Table 1), but also revealed an
additional D816V mutation (case 31, Table 1). Furthermore, in
three ovarian dysgerminoma cases a N822K mutation was found
(cases 21, 24 and 27 Table 1). In total, in eight out of fifteen
ovarian dysgerminoma cases (53%) an exon 17 mutation was
found. One patient (case 28, Table 1), showed a heterozygous
synonymous SNP (rs. 55789615). In case 16 a D820E mutation in
exon 17, next to a N505I mutation in exon 9 was found, being the
only DSD case showing mutations in c-KIT (6%, 1 out of 16). No
mutations in any of the other exons analyzed were found.
Sequence analysis of PDGFRA exon 12, 14 and 18 did not reveal
any mutations, only a homozygous synonymous SNP in exon 12
(rs. 1873778) was detected in all samples analyzed.
Immunohistochemical analysis of c-KIT showed no correlation
between the presence of c-KIT activating mutations and protein
expression in the tumor. In four cases c-KIT immunohistochem-
istry was not investigated (case 23, 25, 29 and 31), as no additional
material was available (Table 1). Staining for c-KIT was variable
in the whole series analyzed, ranging from absent through
intermediate to strong staining and no clear difference between
the DSD and ovarian dysgerminoma subgroups could be seen. As
expected, staining for OCT3/4 was positive in the GB, and
dysgerminoma components in all cases analyzed, with the
exception of case 7. TSPY staining correlated with the two
subgroups of patients analyzed, being positive in the DSD group
(cases 1–16), with the exception of cases 7 and 13, which showed
no staining, and negative in the ovarian dysgerminomas (cases 17–
31) (p-value 3.661028).
Discussion
c-KIT expression has been demonstrated in a wide variety of
human tumors, although in most types expression is variable. The
highest percentages are seen in gastro-intestinal tumors, seminomas,
adenoid-cystic carcinomas and malignant melanomas, and amplifi-
cation and enhanced expression is associated with seminoma
progression [10,30]. The presence of activating mutations of c-KIT
in testicular seminomas is well known. Although ovarian dysgermi-
nomas resemble seminomas in morphology and chromosomal
aberrations [31], expression of c-KIT is not extensively explored.
Here we analyzed fifteen cases of pure ovarian dysgerminomas and
found that c-KIT is expressed, although variable, in all but two of the
cases analyzed.Mutations in c-KIT codon 816were found in 5 (33%)
and mutations in codon 822 in 3 (20%) out of the 15 pure ovarian
dysgerminoma cases (case 17, 19, 22, 25, 31 and 21, 24, 27
respectively, Table 1), accounting for 53% of cases analyzed. No
mutations were detected in c-KIT exon 8, 9, 11, and 13. Although
most ovarian dysgerminomas express c-KIT, we could not find a
correlation between expression and c-KIT exon 17 mutations. It is
known that inGIST inaddition tomutations in c-KIT, alsomutations
inPDGFRA exon12, 14and18play a role and that these aremutually
exclusive [9]. SequencingPDGFRAdidnot revealmutations in anyof
the dysgerminoma DNA samples analyzed, only a variation in exon
12 was found in almost all cases (homozygous synonymous SNP, rs.
1873778, Table 1). This indicates that mutations in PDGFRA do not
play a major role in the development of (ovarian) dysgerminomas or
GB. The results shown here extend those of Cheng et al. and Hoei-
Hansen et al. [16,32]. Cheng et al. [32] analyzed 22 cases of
dysgerminoma and found a c-KIT codon 816 mutation in 27% of
cases, and KIT expression in 87%. Hoei-Hansen et al. found c-KIT
codon 816 mutations in five out of seventeen dysgerminoma cases
(29%) with 80% expressing c-KIT [16]. Furthermore, also in gastro-
intestinal tumors KITmutation rate is lower than the expression rate
ofKIT[33,34].Theresultspresentedheresuggest that inabouthalfof
ovarian dysgerminomas activating mutations in c-KIT play a role,
with about a third consisting of codon 816 mutations, as has been
reported by others [16,32], while the remaining 20% consisted of
N822K mutations. Indeed, c-KITN822Kmutations have also been
foundintesticularGCC[10,35,36], indicatingarole for thismutation
in the development ofGCC, independent of the origin in the testis or
ovary. Next to these mutations a known synonymous SNP
(rs55789615) was detected in exon 17 of case 28, which has been
describedbefore inapatienthavingaN822Kmutation in theGCCof
the contralateral testis [36]. Besides these, no other aberrations in the
exons analyzed could be found in the group of ovarian dysgermino-
mas. Patients showing expression of c-KIT might benefit from
targeted therapy with imatinib mesylate, as has been shown for
patients with GIST [37], and also in a patient with metastatic
seminoma [38]. This might therefore also be of interest to treat
ovarian dysgerminoma.
DSD patients with gonadal dysgenesis or hypovirilization have
an increased risk of developing GCC, with GB as the precursor
lesion, linked to the presence of (part of) the Y-chromosome. Y-
chromosomal material is detected in 90% of patients with
dysgenetic gonads, with the TSPY gene being seen as the
candidate gene in the GonadoBlastoma on the Y-chromosome
(GBY) region [39]. Interestingly, the role of TSPY has been
suggested to be a repressor of androgen signaling by trapping AR
in the cytoplasm, even in presence of the ligand [40]. It is therefore
possible that the relative high levels of TSPY protein found in CIS
and GB creates a local androgen –insensitivity environment, in
which these cells are not able to respond to the presence of ligand.
This is of particular interest during the window of so-called mini-
puberty, whereby the affected germ cells remain in an embryonic
state (positive for OCT3/4 amongst others). During puberty these
cells might become sensitive to prolonged and increased levels of
androgens and subsequently become invasive (associated by loss of
TSPY expression). Here we show that in 89% of cases (17 out of
19 analyzed) where GB was present, either with or without
dysgerminoma, positive staining of the TSPY protein could be
seen in the neoplastic cells. It is possible that in the two TSPY
negative cases (7 and 13) the staining was sub-optimal due to poor
tissue fixation, as other markers tested showed unexpected
(negative) results (data not shown). In contrast, all cases with
ovarian dysgerminoma in a 46,XX (normal female) genetic
background were negative for TSPY. The results underline the
importance of presence of (part of) the Y-chromosome in the
development of GB and point to the fact that in the case of DSD
and ovarian dysgerminomas the pathways leading to the tumors
are distinct. This is in line with, and extends the results reported by
Hoei-Hansen [16], who showed TSPY in five out of seven cases
with GB, the precursor lesion of dysgerminoma in DSD patients,
and no TSPY protein expression in eleven pure dysgerminoma
cases. Presence of the TSPY gene in malignant ovarian germ cell
tumors has also been studied by Shahsiah et al. [41], showing
positivity of the gene in 6 out of 47 (12.7%) cases, two patients
showed GB and in one patient presence of the Y chromosome was
confirmed cytogenetically. However, no c-KIT mutation analysis
was performed.
Next to the presence of TSPY, also presence of OCT3/4 was
investigated in this series. OCT3/4 is one of the key regulators of
self renewal and pluripotency of embryonic stem cells, and in
normal development this protein is only present in primordial
germ cells/gonocytes and oogonia [28,42]. In the testis expression
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is only seen in GCC (i.e. seminoma and embryonal carcinoma)
and its precursor lesion CIS [25,43]. In DSD patients OCT3/4
expression is present in GB and dysgerminoma [44,45]. OCT3/4
was present in all but one GB analyzed in this study, and also a
positive staining was found in all dysgerminomas, in line with
previous studies [16,44]. Case 7 which did not show a positive
OCT3/4 staining of the GB, also gave mixed results using other
markers (negative TSPY staining amongst others), indicating
possible poor quality of the material.
Analyzing the presence of c-KIT activating - and PDGFRA
mutations, either by LightCycler melting curve analysis or
conventional sequencing, in the group of sixteen DSD cases
showing GB, with or without an invasive tumor, showed that in
the majority of cases no mutations could be detected (15 out of 16
cases, 94%). It must be mentioned however, that in a number of
cases the percentage of tumor present in the sample was low,
possibly leading to false negative results. In three patients a shift in
melting curve not corresponding to one of the c-KIT c.816
mutations investigated was found, and subsequent sequencing of
the LightCycler products revealed a wild type exon 17 sequence in
case 1 and 2, and a known synonymous SNP (rs 55789615) in case
4 (I798I), although this latter finding was not confirmed by
conventional sequencing of the original DNA sample. Strikingly,
these three patients all have bilateral disease. The I798I variant
was also detected in a patient with ovarian dysgerminoma (case 28,
see above). In one patient (case 16) showing GB and mainly
dysgerminoma, missense mutations in c-KIT were found in exon 9
and 17, resulting in N505I and D820E respectively, which were
not present in normal adjacent adnexal material. In this case,
which was also positive for TSPY, presence of the Y-chromosome
was confirmed with fluorescent in-situ hybridization on paraffin
embedded material of the dysgerminoma lesion using a Y-
centromeric probe (data not shown), confirming a 46,XY-DSD
diagnosis. A mutation in c-KIT codon 816 in a DSD patient
presenting with GB and dysgerminoma has also been reported
previously [16], indicating that in rare cases these mutations can
be found in DSD patients. Interestingly, the phenotypically male
patient described here presented with a unilateral cryptorchid
testis, which was removed during orchidopexy. He has two sons,
who both presented with bilateral cryptorchid testis, which is one
of the major risk factors for testicular GCC [46]. If the mutations
found are also present in the sons cannot be ascertained as no
material is available for analysis. To our knowledge this is the first
time a N505I mutation in exon 9 of c-KIT has been found. c-KIT
mutations in exon 9 have been described in GIST [47], and it is
thought that these mutations mimic the conformational change
that the extracellular KIT receptor undergoes when SCF is bound
[48]. The activating c-KIT D820E mutation has been described
together with mutations in exon 9, related to sunitinib resistance in
GIST [49]. If the mutations found are located on the same or
different alleles cannot be determined, as only paraffin embedded
material was available for analysis. Besides the specific c-KIT c.816
mutations investigated here, other mutations in exon 17 have been
reported in GCC; c-KIT gain-of-function D820G and Y823D
[2,10,35,36] have been found, next to S821F, C809S, Y823N and
D816E together with D820H [12,36] amongst others, which are
not present in the cases analyzed here, and thus do not seem to be
involved in ovarian dysgerminomas or DSD. Interestingly,
recently genome-wide association studies of have identified SNPs
within KITLG (SCF) as having the strongest association with an
increased risk of developing a testicular GCC, pointing to the
importance of the SCF-cKIT pathway in this disease [50,51,52].
Taken together, c-KIT mutations occur in approximately half of
pure ovarian dysgerminoma cases, all residing in exon 17,
indicating a role in the etiology of the disease. The activated c-
KIT, together with prolonged expression of OCT3/4 may allow
increased survival and proliferation of undifferentiated gonocytes/
oogonia, leading to the development of dysgerminoma. In DSD,
presence of Y-chromosomal material leads to the gonadal
dysgenesis, in which the germ cells survive because of prolonged
expression of both OCT3/4 and TSPY, setting the stage for GB
and subsequent dysgerminoma development; although in a
minority of cases mutations in c-KIT might play a role.
Supporting Information
Figure S1 Detection of c-KIT c.816 mutations in patient
samples by melting curve analysis. The y-axis represents
fluorescence intensity and the x-axis represents temperature.
Mutations lead to different melting temperatures of the hybrid-
ization probes from the amplification product. A, B) Melting
curves of sample 19 and 22 with and without the addition of LNA
are shown together with a positive control harboring the D816V
mutation. C) Melting curves of sample 17 with and without the
addition of LNA are shown together with a positive control
harboring the D816H mutation. D) Melting curves of sample 25
with and without the addition of LNA are shown together with a
positive control harboring the D816Y mutation. E, F) Electro-
pherogram showing the A to T mutation in codon 816 in
LightCycler products with and without LNA added of sample 19
and 22 respectively. G) Electropherogram showing the G to C
mutation in LightCycler products with and without LNA added of
codon 816 in sample 17. H) Electropherogram showing the G to T
mutation in LightCycler products with and without LNA added of
codon 816 in sample 25. Note the suppression of wild type c-KIT
and the enrichment of the mutant amplification product in the +
LNA samples. pc: positive control, Val: valine mutation, His:
histidine mutation, Tyr: tyrosine mutation, LNA: locked nucleic
acid.
(TIF)
Table S1 c-KIT and PDGFRA primers.
(XLS)
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